IPVS Board

Margaret Stanley

Professor Margaret Stanley
Department of Pathology
University of Cambridge

Suzanne Garland

Department of Microbiology and Infectious Diseases, Royal Women’s Hospital, Department of Microbiology, RCH Honorary Research Fellow, Murdoch Childrens Research Institute Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne, Australia

Silvia De Sanjosé

Director of Scale-up project Reproductive Health Global Program PATH

Robert D. Burk

Professor and Vice Chair for Translational Research Department of Pediatrics (Division of Genetic Medicine) Professor, Departments of Microbiology & Immunology; Epidemiology & Population Health; and, Obstetrics, Gynecology & Women's Health

Michelle Adair Ozbun

Professor, Departments of Molecular Genetics & Microbiology; Obstetrics and Gynecology, The University of New Mexico School of Medicine Co-Leader, Head and Neck Cancer Clinical Working Group, The University of New Mexico Comprehensive Cancer Center

Thomas R. Broker

Biochemistry & Molecular Genetics
University of Alabama

Joel Palefsky

M.D., C.M., F.R.C.P.(C). Professor of Medicine at the University of California San Francisco School of Medicine. His interests include the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center. He is the chair of the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study, a national multi-site NIH study designed to determine whether treatment of anal cancer precursor lesions prevents the development of anal cancer. He is the founder and past president of the International Anal Neoplasia Society and is the past president of the International Papillomavirus Society (IPVS). He continues to serve on the board of IPVS and leads the IPVS International HPV Awareness Day Campaign.

Joakim Dillner

Anna-Barbara Moscicki

Professor of Pediatrics at UCLA, Division Chief of Adolescent and Young Adult Medicine.
Associate Executive Chair for Clinical Research,
and Chair, Clinical Trials Committee for Pediatrics

Deborah Watson-Jones

Marc Steben

Medical Director, Clinique A rue McGill, Medical Advisor at the STI Unit of Quebec’s National Public Health Institute

Talía Malagón

Postdoctoral Fellow, McGill University, Division of Cancer Epidemiology, Canada

Aimee Kreimer

Infectious Disease Epidemiologist
Senior Investigator, Division of Cancer Epidemiology and Genetics
US National Cancer Institute
National Institutes of Health

Jo Waller

Reader in Cancer Behavioural Science | Cancer Prevention Group | School of Cancer & Pharmaceutical Sciences | Faculty of Life Sciences & Medicine | King’s College London

Dr. Jo Waller is a Reader in Cancer Behavioural Science at King’s College London. With a background in health psychology, she has over 20 years’ experience of research on the psychological and behavioural aspects of cancer prevention and early diagnosis. Funded by a prestigious career development fellowship from Cancer Research UK, her recent focus has been on understanding non-participation in cervical screening and HPV vaccination and developing interventions to increase informed uptake. Dr Waller led the psychological evaluation of primary HPV screening in England and works closely with the NHS cervical screening programme to develop evidence-based communication materials to facilitate informed choice about screening and mitigate adverse psychological responses to HPV-positive results. She sits on the advisory committees for the breast and cervical screening programmes in England. Dr Waller is an honorary visiting professor at the Institute of Epidemiology and Healthcare at UCL and co-chairs the UK Society for Behavioural Medicine’s special interest group on cancer prevention and screening.

Ana Cecilia Rodriguez

MD, Consultant at the Division of Cancer Epidemiology & Genetics, US National Cancer Institute.

Ana Cecilia Rodríguez is a medical doctor with a specialization in public health from the University of Costa Rica. She is a consultant to the Division of Cancer Epidemiology and Genetics at the National Cancer Institute, USA.

Early in her career Dr. Rodríguez built her expertise as a field epidemiologist investigating health related effects and pesticide exposure in rural Costa Rican communities. She oversaw the introduction of electronic record keeping and data analysis into the Costa Rican National Tumor Registry and served as its director for two years. Dr. Rodríguez has dedicated much of her career to researching the natural history of cervical neoplasia and HPV infection and cervical cancer prevention strategies including HPV vaccination, screening, and detection of cervical neoplasia. She has served as Principal Investigator and co-Principal Investigator in Costa Rican studies funded by the USA National Cancer Institute including the Proyecto Epidemiologico Guanacaste (PEG) HPV Natural History Study, a 10,049 women longitudinal population-based cohort and the Costa Rican Vaccine Trial (CVT). The data from these and other studies in which she has participated have led to numerous high-impact manuscripts published in peer-reviewed journals. Most recently, Dr. Rodríguez has dedicated her research to international efforts that will develop improved screening, triage, and treatment methods more suitable for underserved and hard-to-reach populations.

Nagayasu Egawa

M.D., PhD.,
Research Associate,
Department of Pathology,
University of Cambridge

Sarah Feldman

MD, MPH , Director Ambulatory Gynecologic Oncology and Center for Pre-invasive Disease of the Lower Genital Tract

Associate Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Brigham and Women’s Hospital

Dr. Feldman studied public and international affairs with a focus on health policy at Princeton University, before receiving her MD and MPH at Harvard University. She is board-certified in obstetrics and Gynecology and Gynecologic Oncology, and has overseen the Colposcopy clinic at BWH for 20 years, where she teaches medical students, residents, and fellows about the prevention and management of HPV-related diseases of the lower genital tract. She oversees numerous research projects in the areas of cervical cancer prevention, and has sat on multiple national and international committees of the SGO, ASCCP, and ASCO related to global and international care of patients either with cervical cancer or preinvasive disease of the lower genital tract. Dr. Feldman has been a panel member or expert reviewer of guidelines for the ASCCP, American Cancer Society, US Preventive Task Force, American Society of Clinical Oncology and FDA in the area of cervical cancer prevention and care for women with cervical cancer in low resource settings. She is currently a co-investigator on two NCI grants aimed at improving and evaluating screening for cervical cancer in the US. She has worked on projects in Rwanda, Kenya, Somalia, China, and Botswana. She also writes extensively in the area of cervical cancer prevention, both nationally and globally, and is passionate about re-thinking and re-imagining care to bring the best care to all women.

Elizabeth McClymont

Eric Chow

Associate Professor, Central Clinical School, Monash University | Melbourne Sexual Health Centre, Alfred Health

Associate Professor Eric Chow is an epidemiologist and biostatistician based at the Melbourne Sexual Health Centre (MSHC) at The Alfred Hospital. He heads the Health Data Management and Biostatistics Unit at MSHC and is an Associate Professor at Central Clinical School, Monash University. He is also an Honorary Principal Fellow at the Melbourne School of Population & Global Health, The University of Melbourne.

A/Prof Chow’s research program aims to improve treatment, prevention and control of sexually transmitted infections (STI), with a particular focus on gonorrhoea and human papillomavirus (HPV). His work focuses on the evaluation of the national school-based HPV vaccination program. He has led several studies looking at the impact of the implementation of the gender-neutral HPV vaccination program (e.g. epidemiology of genital warts and HPV prevalence) and the implementation of time-limited catch-up programme for men who have sex with men (e.g. vaccination uptake). His work on HPV has helped to inform HPV guidelines abroad.